Published in Drug Law Weekly, December 19th, 2006
For the 9 months ended September 30, 2006, the net loss applicable to common stockholders was $4,229,286, or $1.60 per common share, as compared to $4,556,259 or $2.05 per common share, for the same period in 2005. As of September 30, 2006, the company had a total of $1,677,256 in cash and short term investments.
On July 24, 2006, the company's board of directors...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.